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indicatorto distinguish HC from SLN. On the other hand, the LD isoenzymes are unable to discriminate between HC and cirrhosis or between abdominal neoplasia with and without liver metastases.
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hepatobillary disease
Recent studies in clinical enzymology have improved the capacity to differentiate among various chronicliver diseases,including neoplasia (1) (2) (3) (4) (5) (6) . We have previously focused our attention on discriminating between hepatocarcinoma (HC) and cirrhosis (4-6) , which is one of the most frequently encountered differential diagnoses in the field of hepatobiliary diseases. 4 Various patterns of serum y-glutamyltransferase isoforms have been proposedas specificindicators of these diseases; in addition, a faster anodic y-glutamyltransferase isoform has been identified as a specific serum signal of HC. We designed a study to investigate the activity concentrations of total lactate dehydrogenase (LI); EC 1.1.1.27) and its isoenzymes in sera of patients affected by cirrhosis, HC, SLN mainly from an abdominal site, and AN without liver met.astases,to try to contribute to the above-mentioned differential diagnoses.
Patients and Methods

Patients
We studied all the new patients admitted to the The number of casesstudied does not reflect the exact prior prevalence of each disease in the Naples area, but it does reflect the prevalence of admission to a specialized medical (nonsurgical) Hepatology Division.
Methods
Sera from the patients were collected and immediately processed for U) and U) isoenzyme We evaluated total U) serum activity with a Hitachi 737 automatic analyzer (Boehringer Biochemia, Mannhelm, F.R.G.), using reagents from the same company; the reference values for healthy subjects were 227-450 U/Lat37#{176}C. U) isoenzymes were analyzed by a cellulose acetate electrophoretic procedure (procedure and materials from Helena Laboratories,Beaumont, TX). The reference intervals for the U) isoenzymes in healthy subjects were as follows: U)-1, 17-31%; LD-2,30-39%;  19-29%; LD-4, 4-12%; LD-5, 3-11%. Although this method is not absolutely accurate, it is one of the most widely used in routine practice (see 9), and the extent of its variability could not affect the validity of the results obtained in this study.
We performed one-way analysis of variance (ANOVA) statistical analysis (10) with multiple comparisons between groups (Scheff#{233} test) (11), using the SPSS PC program (SPSS Inc., Chicago, IL). The discriminatory power of the test, which in our case is the percentages of subjects correctly classified between two diseases, is equivalent to the diagnosticefficiency calculated according to Galen and Gambino (12). Some of the analytes shown in Table 2 clearly differentiated between cirrhosis and SLN. However, again, the results are not reported because these findings cannot be exploited in the clinical situation: cirrhosis is rarely confused with SLN, and SLN is hardly ever found in cirrhotic patients (13) . As shown in Table 2 , some analytes showed a highly significant difference (P <0.001) for some analytes between cirrhosis vs HC and HC vs SLN. The mean value of LD-5 (in UIL) was significantly different in the cirrhosis vs HC comparison but, as shown in the scatterplot (Figure 1) , the values widely overlap in the two groups of patients, so that no effective discriminating cutoff value can be selected. The same results were obtained when percentage U)-5 values were used for the scatterplot (data not shown). The highly significant difference between the two groups can probably be attributed to the very large increase of serum U)-5 in someHC patients, a situation that leads to an asymmetric distribution of the data.
Results
The most interesting result to emerge from the ANOVA analysis is the highly significant difference in the mean values of LD-4 and of the LD-4ILD-5 ratio in HC vs SLN Table 2 (SLN vs AN) only the LD-4 isoenzyme expressed as a percentage was significantly different. However, again the scatterplot showed a wide overlap of the two groups of values (data not shown). Table 3 shows the discriminatory power of the serum U)-4/LD-5 ratio in distinguishing HCfrom SLN. At the cutoff value of 1.05 previously selected (Figure 2B ), 95% of HC cases and 82% of SLN cases were correctly diagnosed. The overall discriminatory power was 91%, which also indicates a diagnostic sensitivity of 82% for patients with SLN in a mixed population of HC and SLN subjects, and a diagnostic specificity of 95% in identifying within the same population the subjectsnot affected by SLN but affected by HC (seeref. 12) . However, as the ROC curve of Figure 2B clearly shows,the clinical use of the LD-4/LD-5 ratio is not to emphasize either one of the two diagnostic characteristics, but to contribute to the discrimination between the two situations. Simulating prevalences of 1:1 or 1:2 for HC vs SLN, which are closer to the real prior prevalence of the diseasesin the general population to which the patients belonged, did not significantly reduce the discriminatory power of the test for HC and SLN: 89% and 87%, respectively. The U)-4/ LD-5 ratio was not statistically correlated to total serum U) activity. In addition, the behavior of the LD-4JLD-5 ratio was the same in patients with normal (27 of 54 patients) and above-normal total U) activity in serum.
DIscussion
Biochemical studies performed so far on the differential diagnosis between HC and SLN have been rather band has been reported in serum from liver cancer patients (14) , but this finding cannot be compared with our resultsbecause it was obtained by agarose gel electrophoresis, whereas our study involved the cellulose acetate procedure.
The serum concentrations of the two currentlyused markers for HC and SLN, namely, carcinoembryonic antigen and a-fetoprotein, respectively, in the two groups of patients (data not reported) showed that carcinoembryonic antigen values almost completely overlapped in the two populations, whereas a-fetoprotein separated HC and SLN patients with a high discriminatory power at a cutoff lower than that used conventionally for normal subjects. Thus, further studies should be conducted to establish whether a-fetoprotein in fact reliably distinguishes between HO and SLN.
Of the laboratory tests used-serum total bilirubin, y.glutamyltransferase, and other cholestatic enzymes, namely, alkaline phosphatase, 5'-nucleotidase (EC 3.1.3.5), and leucine-aminopeptidase (EC 3.4.11.1)-none distinguished HO from SLN. Moreover, the presence of jaundice was not a discriminating factor. Neither did medical records help separate the two groups: most of the hepatocellular carcinomas developedon a pre-existing chronic liver disease; however, some SLN patients also had a history of this type of disease. Finally, viral hepatitis B serologicmarkers, i.e., HBsAg and HBcAb-IgG, did not separate the HO group from the SLN patients.
The biochemical basis of the increase of U)-5 in HC and U)-4 in SLN has yet to be clarified. The increase of LD-5 in sera from HC patients can be explained by the homotetrameric structure of LD-5, whose monomer, the so-called M subunit, is actively synthesized in hepatocytes, particularly during neoplastic transformation (14) . Why large amounts of LD-4 appear in SLN sera is obscure. The increase of LD-4 seen in sera from SLN patients cannot be attributed to high production of the isoenzyme by the primary tumor, because our AN patients without liver metastases did not show increased concentrations of LD-4. Moreover, clinical and laboratory data excluded the possibility that the enhanced LD-4 as well as LD-5 activity resulted from other diseases. Muscle damage was also excluded because creatine kinase activity in serum was within the reference values in all SLN and HO patients we examined.
In conclusion, whatever the mechanism, the LD-4/ LD-5 serum ratio may be used as a rapid, simple, noninvasive procedure when HO must be differentiated from SLN, even when total LD serum activity is within normal range. 
